Zobrazeno 1 - 10
of 76
pro vyhledávání: '"MacConaill LE"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Søndergaard JN, Nazarian R, Wang Q, Guo D, Hsueh T, Mok S, Sazegar H, MacConaill LE, Barretina JG, Kehoe SM, Attar N, von Euw E, Zuckerman JE, Chmielowski B, Comin-Anduix B, Koya RC, Mischel PS, Lo RS, Ribas A, Søndergaard, Jonas N
Publikováno v:
Journal of Translational Medicine; 2010, Vol. 8, p39-39, 1p
Autor:
Yuexiang Wang, Mark A. Rubin, Michelangelo Fiorentino, Franco Roviello, Alissa C. Baker, Matthew Meyerson, Sarah M. Kehoe, William C. Hahn, Keluo Yao, Deborah J. Goff, Levi A. Garraway, Jennifer A. Chan, Ramesh A. Shivdasani, Laura E. MacConaill, Jonathan A. Fletcher, Lauren Luongo, Megan Hanna, Matthew J. Davis, Keith L. Ligon, Lili Niu, Caroline Emery, Adam J. Bass, Charlie Hatton, Kornelia Polyak, G. Corso, Sandro Santagata, Mark W. Kieran, Charles D. Stiles, Catarina D. Campbell, Juliet Philips, Chandrani Mondal
Publikováno v:
PLoS ONE
PLoS ONE, Vol 4, Iss 11, p e7887 (2009)
PLoS ONE, Vol 4, Iss 11, p e7887 (2009)
BACKGROUND: Detection of critical cancer gene mutations in clinical tumor specimens may predict patient outcomes and inform treatment options; however, high-throughput mutation profiling remains underdeveloped as a diagnostic approach. We report the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2fd7d0e2687fc5514afe65b5f594e63f
http://europepmc.org/articles/PMC2774511
http://europepmc.org/articles/PMC2774511
Autor:
Dennis MJ; Center for Head & Neck Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Michael_dennis@dfci.harvard.edu.; Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana Building, Room 2128, Boston, MA, 02215, USA. Michael_dennis@dfci.harvard.edu., Pavlick DC; Foundation Medicine Inc., Boston, MA, USA., Kacew A; Pritzker School of Medicine, The University of Chicago, Chicago, IL, USA., Wotman M; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., MacConaill LE; Department of Pathology, Mass General Brigham, Boston, MA, USA., Jones SM; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Pfaff KL; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Rodig SJ; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA., Eacker S; Phase Genomics Inc., Seattle, WA, USA., Malig M; Phase Genomics Inc., Seattle, WA, USA., Reister E; Phase Genomics Inc., Seattle, WA, USA., Piccioni D; Moores Cancer Center, University of California San Diego Health, La Jolla, CA, USA., Kesari S; Pacific Neuroscience Institute, Santa Monica, CA, USA., Sehgal K; Center for Head & Neck Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Haddad RI; Center for Head & Neck Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Cohen E; Moores Cancer Center, University of California San Diego Health, La Jolla, CA, USA., Posner MR; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Deichaite I; University of California San Diego, La Jolla, CA, USA., Hanna GJ; Center for Head & Neck Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Publikováno v:
Journal of translational medicine [J Transl Med] 2024 Oct 22; Vol. 22 (1), pp. 960. Date of Electronic Publication: 2024 Oct 22.
Autor:
Forrest SJ; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA. Suzanne_Forrest@dfci.harvard.edu.; Harvard Medical School, Boston, MA, USA. Suzanne_Forrest@dfci.harvard.edu., Gupta H; Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Ward A; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA., Li YY; Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Doan D; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA., Al-Ibraheemi A; Harvard Medical School, Boston, MA, USA.; Boston Children's Hospital, Boston, MA, USA., Alexandrescu S; Harvard Medical School, Boston, MA, USA.; Boston Children's Hospital, Boston, MA, USA., Bandopadhayay P; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Shusterman S; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Mullen EA; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Collins NB; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Chi SN; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Wright KD; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Kumari P; Dana-Farber Cancer Institute, Boston, MA, USA., Mazor T; Dana-Farber Cancer Institute, Boston, MA, USA., Ligon KL; Harvard Medical School, Boston, MA, USA.; Dana-Farber Cancer Institute, Boston, MA, USA.; Boston Children's Hospital, Boston, MA, USA.; Brigham and Women's Hospital, Boston, MA, USA., Shivdasani P; Brigham and Women's Hospital, Boston, MA, USA., Manam M; Boston Children's Hospital, Boston, MA, USA., MacConaill LE; Brigham and Women's Hospital, Boston, MA, USA., Ceca E; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA., Benich SN; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA., London WB; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA., Schilsky RL; American Society of Clinical Oncology, Alexandria, VA, USA., Bruinooge SS; American Society of Clinical Oncology, Alexandria, VA, USA., Guidry Auvil JM; National Cancer Institute, Bethesda, MD, USA., Cerami E; Dana-Farber Cancer Institute, Boston, MA, USA., Rollins BJ; Harvard Medical School, Boston, MA, USA.; Dana-Farber Cancer Institute, Boston, MA, USA.; Brigham and Women's Hospital, Boston, MA, USA., Meyerson ML; Harvard Medical School, Boston, MA, USA.; Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Lindeman NI; Weill Cornell Medical College, New York, NY, USA., Johnson BE; Harvard Medical School, Boston, MA, USA.; Dana-Farber Cancer Institute, Boston, MA, USA.; Brigham and Women's Hospital, Boston, MA, USA., Cherniack AD; Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Church AJ; Harvard Medical School, Boston, MA, USA.; Boston Children's Hospital, Boston, MA, USA., Janeway KA; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA. Katherine_Janeway@dfci.harvard.edu.; Harvard Medical School, Boston, MA, USA. Katherine_Janeway@dfci.harvard.edu.
Publikováno v:
Nature communications [Nat Commun] 2024 Aug 22; Vol. 15 (1), pp. 7218. Date of Electronic Publication: 2024 Aug 22.
Autor:
Forrest SJ; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA. Suzanne_Forrest@dfci.harvard.edu.; Harvard Medical School, Boston, MA, USA. Suzanne_Forrest@dfci.harvard.edu., Gupta H; Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Ward A; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA., Li YY; Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Doan D; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA., Al-Ibraheemi A; Harvard Medical School, Boston, MA, USA.; Boston Children's Hospital, Boston, MA, USA., Alexandrescu S; Harvard Medical School, Boston, MA, USA.; Boston Children's Hospital, Boston, MA, USA., Bandopadhayay P; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Shusterman S; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Mullen EA; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Collins NB; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Chi SN; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Wright KD; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Kumari P; Dana-Farber Cancer Institute, Boston, MA, USA., Mazor T; Dana-Farber Cancer Institute, Boston, MA, USA., Ligon KL; Harvard Medical School, Boston, MA, USA.; Dana-Farber Cancer Institute, Boston, MA, USA.; Boston Children's Hospital, Boston, MA, USA.; Brigham and Women's Hospital, Boston, MA, USA., Shivdasani P; Brigham and Women's Hospital, Boston, MA, USA., Manam M; Boston Children's Hospital, Boston, MA, USA., MacConaill LE; Brigham and Women's Hospital, Boston, MA, USA., Ceca E; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA., Benich SN; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA., London WB; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA., Schilsky RL; American Society of Clinical Oncology, Alexandria, VA, USA., Bruinooge SS; American Society of Clinical Oncology, Alexandria, VA, USA., Guidry Auvil JM; National Cancer Institute, Bethesda, MD, USA., Cerami E; Dana-Farber Cancer Institute, Boston, MA, USA., Rollins BJ; Harvard Medical School, Boston, MA, USA.; Dana-Farber Cancer Institute, Boston, MA, USA.; Brigham and Women's Hospital, Boston, MA, USA., Meyerson ML; Harvard Medical School, Boston, MA, USA.; Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Lindeman NI; Weill Cornell Medical College, New York, NY, USA., Johnson BE; Harvard Medical School, Boston, MA, USA.; Dana-Farber Cancer Institute, Boston, MA, USA.; Brigham and Women's Hospital, Boston, MA, USA., Cherniack AD; Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Church AJ; Harvard Medical School, Boston, MA, USA.; Boston Children's Hospital, Boston, MA, USA., Janeway KA; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA. Katherine_Janeway@dfci.harvard.edu.; Harvard Medical School, Boston, MA, USA. Katherine_Janeway@dfci.harvard.edu.
Publikováno v:
Nature communications [Nat Commun] 2024 Jul 11; Vol. 15 (1), pp. 5837. Date of Electronic Publication: 2024 Jul 11.
Autor:
Min J; Genetics Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA., Zaslavsky A; Department of Cancer Biology, Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA., Fedele G; Harvard Medical School, Boston, Massachusetts, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., McLaughlin SK; Genetics Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA., Reczek EE; Genetics Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA., De Raedt T; Genetics Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA., Guney I; Harvard Medical School, Boston, Massachusetts, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Strochlic DE; Harvard Medical School, Boston, Massachusetts, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., MacConaill LE; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Beroukhim R; Harvard Medical School, Boston, Massachusetts, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, Massachusetts, USA., Bronson RT; Harvard Medical School, Boston, Massachusetts, USA., Ryeom S; Department of Cancer Biology, Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA., Hahn WC; Harvard Medical School, Boston, Massachusetts, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, Massachusetts, USA., Loda M; Harvard Medical School, Boston, Massachusetts, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA.; Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Cichowski K; Genetics Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA. kcichowski@rics.bwh.harvard.edu.; Harvard Medical School, Boston, Massachusetts, USA. kcichowski@rics.bwh.harvard.edu.; Ludwig Center at Dana-Farber/Harvard Cancer Center, Boston, Massachusetts, USA. kcichowski@rics.bwh.harvard.edu.
Publikováno v:
Nature medicine [Nat Med] 2024 Jun; Vol. 30 (6), pp. 1790.
Autor:
Vega DM; Friends of Cancer Research, Washington., Yee LM; National Cancer Institute, Bethesda., McShane LM; National Cancer Institute, Bethesda., Williams PM; Molecular Characterization Laboratory, Frederick National Lab for Cancer Research, Leidos Biomedical Research Inc., Frederick., Chen L; Molecular Characterization Laboratory, Frederick National Lab for Cancer Research, Leidos Biomedical Research Inc., Frederick., Vilimas T; Molecular Characterization Laboratory, Frederick National Lab for Cancer Research, Leidos Biomedical Research Inc., Frederick., Fabrizio D; Foundation Medicine Inc., Cambridge., Funari V; NeoGenomics Laboratories, Aliso Viejo, USA., Newberg J; Foundation Medicine Inc., Cambridge., Bruce LK; NeoGenomics Laboratories, Aliso Viejo, USA., Chen SJ; ACT Genomics, Taipei, Taiwan., Baden J; Bristol Myers Squibb Co., Princeton., Carl Barrett J; AstraZeneca Pharmaceuticals LP, Waltham, USA., Beer P; European Organisation for Research and Treatment of Cancer, Brussels, Belgium., Butler M; LGC Clinical Diagnostics, Gaithersburg., Cheng JH; ACT Genomics, Taipei, Taiwan., Conroy J; OmniSeq Inc., Buffalo., Cyanam D; Clinical Sequencing Division, Thermo Fisher Scientific, Ann Arbor., Eyring K; Intermountain Precision Genomics, St. George., Garcia E; Brigham and Women's Hospital, Boston, USA., Green G; Bristol Myers Squibb Co., Princeton., Gregersen VR; QIAGEN Inc, Aarhus, Denmark., Hellmann MD; Memorial Sloan Kettering Cancer Center, New York., Keefer LA; Personal Genome Diagnostics, Baltimore., Lasiter L; Friends of Cancer Research, Washington., Lazar AJ; The University of Texas MD Anderson Cancer Center, Houston., Li MC; National Cancer Institute, Bethesda., MacConaill LE; Brigham and Women's Hospital, Boston, USA., Meier K; Illumina Inc, Clinical Genomics, San Diego., Mellert H; Biodesix, Inc., Boulder., Pabla S; OmniSeq Inc., Buffalo., Pallavajjalla A; Johns Hopkins University, Baltimore., Pestano G; Biodesix, Inc., Boulder., Salgado R; European Organisation for Research and Treatment of Cancer, Brussels, Belgium., Samara R; QIAGEN Inc, Aarhus, Denmark., Sokol ES; Foundation Medicine Inc., Cambridge., Stafford P; Caris Life Sciences Inc, Phoenix, Arizona, USA., Budczies J; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany., Stenzinger A; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany., Tom W; Clinical Sequencing Division, Thermo Fisher Scientific, Ann Arbor., Valkenburg KC; Personal Genome Diagnostics, Baltimore., Wang XZ; EMD Serono Research and Development Institute, Inc., Billerica., Weigman V; Q Squared Solutions, Durham., Xie M; AstraZeneca Pharmaceuticals LP, Waltham, USA., Xie Q; General Dynamics Information Technology, Inc., Columbia, USA., Zehir A; Memorial Sloan Kettering Cancer Center, New York., Zhao C; Illumina Inc, Clinical Genomics, San Diego., Zhao Y; National Cancer Institute, Bethesda., Stewart MD; Friends of Cancer Research, Washington. Electronic address: mstewart@focr.org., Allen J; Friends of Cancer Research, Washington.
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2024 Jan; Vol. 35 (1), pp. 145. Date of Electronic Publication: 2023 Aug 08.
Autor:
Nassar AH; Department of Hematology/Oncology, Yale New Haven Hospital, New Haven, CT 06510, USA; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA., Adib E; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA., Abou Alaiwi S; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA., El Zarif T; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Groha S; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Akl EW; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA., Nuzzo PV; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Mouhieddine TH; Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, New York, NY 10029, USA., Perea-Chamblee T; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA., Taraszka K; Department of Computational Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA., El-Khoury H; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Labban M; Department of Urologic Surgery, Brigham and Women's Hospital, Boston, MA 02115, USA., Fong C; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA., Arora KS; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA., Labaki C; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Xu W; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Sonpavde G; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Haddad RI; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Mouw KW; Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Giannakis M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Hodi FS; Melanoma Center, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Zaitlen N; Department of Computational Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA., Schoenfeld AJ; Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, 1275 York Avenue, New York, NY 10065, USA., Schultz N; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA., Berger MF; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA., MacConaill LE; Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Ananda G; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Kwiatkowski DJ; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA., Choueiri TK; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Schrag D; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA., Carrot-Zhang J; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA., Gusev A; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Division of Genetics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA. Electronic address: alexander_gusev@dfci.harvard.edu.
Publikováno v:
Cancer cell [Cancer Cell] 2022 Oct 10; Vol. 40 (10), pp. 1161-1172.e5. Date of Electronic Publication: 2022 Sep 29.